Vifor Pharma Group Ltd is a global specialty pharmaceutical company headquartered in St. Gallen, Switzerland, trading over-the-counter under the symbol GNHAY. The company focuses on the development, manufacturing and commercialization of products addressing iron deficiency, nephrology and cardio-renal conditions. Vifor Pharma operates through a combination of in-house capabilities and strategic partnerships to bring innovative therapies to patients worldwide.
Its product portfolio includes intravenous iron therapies such as Venofer® and Ferinject® (Injectafer® in the U.S.), which are used to treat iron deficiency anemia in a range of patient populations, including those with chronic kidney disease. In the nephrology segment, Vifor Pharma offers a suite of compounds for dialysis and kidney disease management, including phosphate binders and injectable agents to control mineral and bone disorders. The company has also expanded into cardio-renal markets with treatments that address complications arising from heart failure and hyperkalemia.
Vifor Pharma is active across Europe, North America and the Asia-Pacific region, leveraging a direct sales force in key markets and partnering with local distributors in emerging territories. Its research and development organization collaborates with academic institutions and biotech firms to advance pipeline candidates in iron metabolism and rare disease areas. Recent regulatory approvals and label extensions have strengthened the company’s presence in the U.S. and European markets, underscoring its commitment to broadening patient access.
The company traces its origins to the Galenica Group, with a heritage dating back to the early 20th century in Switzerland. Through a strategic demerger in 2020, Vifor Pharma emerged as an independent, pure-play specialty pharma organization. Since then, it has pursued both organic growth and targeted acquisitions to enhance its therapeutic offerings and reinforce its global footprint.
AI Generated. May Contain Errors.
